ADIAL PHARMACEUTICALS, INC. (ADIL) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US00688A3041

Price
4.05 USD
Market cap
2.71 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

ADIAL PHARMACEUTICALS, INC. financials

Fiscal year2025
Operating income-7.80 m USD
EBIT-8.13 m USD
Net income-7.98 m USD
Diluted EPS – continuing operations-11.93 USD

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ADIAL PHARMACEUTICALS, INC.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 04.11.2026. Details in the risk notice.